| Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
| Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
| Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[9] Azithromycin: Savaris RF, Teixeira LM, Torres TG, Edelweiss MI, Moncada J, Schachter J. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. ObstetGynecol.2007Jul;110(1):53-60.http://www.ncbi.nlm.nih.gov/pubmed/17601896
Azithromycin (LAP/ SSW/ BUBO): AmsdenGW, Gray CL. Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. J AntimicrobChemother.2001Jan;47(1):61-6. http://www.ncbi.nlm.nih.gov/pubmed/11152432
Azithromycin (LAP/ SSW/ BUBO): Sampson MR, DumitrescuTP, Brouwer KL, Schmith VD. Population pharmacokinetics of azithromycin in whole blood, peripheral blood mononuclear cells, and polymorphonuclear cells in healthy adults.CPTPharmacometricsSystPharmacol.2014 Mar 5;3:e103. http://www.ncbi.nlm.nih.gov/pubmed/24599342